• Aastrom Biosciences Inc., of Ann Arbor, Mich., formed an independent steering committee to oversee its REVIVE Phase III trial of ixmyelocel-T led by William Hiatt. The people who are assigned to the committee include Michael Conte, William Marston, Richard Powell and Michael Smith.

• Ablexis LLC, of San Francisco, appointed Jake Bauer senior director of corporate development and business operations.

• Advaxis Inc., of Princeton, N.J., appointed Chris L. French executive director of medical affairs.

• Adventrx Pharmaceuticals Inc., of San Diego, appointed Gregory D. Gorgas senior vice president, commercial.

• Agennix AG, of Planegg, Germany, appointed Jill Porter senior vice president of pharmaceutical development and appointed Christine Boisclair senior vice president of global regulatory affairs.

• Allon Therapeutics Inc., of Vancouver, British Columbia, appointed Michael Aldridge to its board.